Applied Filters
WHO to make biosimilars more available in poor countries
The World Health Organization will launch a pilot project for biosimilars to make costly cancer treatments more widely available in low and middle income countries.
Hepatitis C drugs face four patent challenges in India
India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.
IP strategy chief focus for life sciences counsel, says report
Global intellectual property strategy will be the chief area of focus for IP counsel in the life sciences arena in 2017.
WTO amends TRIPS to ease poor countries’ access to medicine
The World Trade Organization has amended its intellectual property rules to make it easier for poor countries to access affordable medicines.
Australia should change patent extension approach, says report
A report released by the Australian government has said Australia's extension of term scheme for patents in the pharmaceutical industry "has had little effect" on investment and innovation.
Phylogica and Genentech extend collaboration for antibiotic research
Phylogica, an Australian drug discovery company, has extended its research collaboration and licensing agreement with Genentech to discover novel antibiotics.
Mylan enters MPP agreement over affordable hepatitis C generics
Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool, a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.
Sanofi and Genzyme recover domain at WIPO
Pharmaceutical company Sanofi and its subsidiary Genzyme have recovered a domain name that infringed a trademark at the World Intellectual Property Organization’s Arbitration and Mediation Center.
Novartis wins growth hormone domain dispute
Healthcare company Novartis has won a domain name dispute at the World Intellectual Property Organization Arbitration and Mediation Center.
AstraZeneca to divest Rhinocort Aqua rights outside US
AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US.
